Drug Type Antibody drug conjugate (ADC) |
Synonyms HM2-drug conjugate, Trastuzumab-drug conjugate + [2] |
Target |
Action antagonists, inhibitors |
Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), Tubulin inhibitors, ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Stomach Cancer | Phase 1 | China | - | |
Metastatic human epidermal growth factor 2 positive carcinoma of breast | Preclinical | South Korea | 11 Jan 2018 |
Phase 1 | 27 | yhyxprkkao(lwvscciajj) = alopecia occurred in 6 patients kcwegliheo (ahfcveohmt ) View more | Positive | 25 May 2020 |